At what enterprise value was LABORIZON acquired in 2020?

During the acquisition of LABORIZON by BIOGROUP in 2020, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LABORIZON when it was acquired by BIOGROUP?

The estimated EV/EBITDA multiple for LABORIZON is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was LABORIZON acquired by BIOGROUP?

LABORIZON was acquired by BIOGROUP in 2020.

What was the revenue of LABORIZON at the time of the deal?

The revenue of LABORIZON at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LABORIZON during the acquisition?

LABORIZON's EBITDA is estimated to be in the range of 25M - 50M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LABORIZON acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LABORIZON deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/nos-exclus/analyses-medicales-laborizon-devrait-sunir-a-biogroup-1186395

← DATABASE

Home Database Healthcare & PharmaLABORIZON

07/2020

LABORIZON acquired by BIOGROUP

FRANCE Health Providers / Healthcare Facilities / Labs (Biology) EV 300M - 700M EUR

Context

Biogroup acquired Laborizon. This strategic move allowed Biogroup to expand its footprint in Western France (Brittany, Normandy, Centre Val de Loire) and strengthen its position as a French leader alongside Cerba. The deal was finalized despite the COVID-19 pandemic, which underscored the critical nature of medical analysis infrastructure.

LABORIZON, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

A major regional medical biology group formed by the merger of five laboratory groups. It operates approx. 100 local sites and 6 technical platforms, serving the Center, Normandy, and Brittany regions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2020	EQT PARTNERS	COLISÉE	FRANCE	Nursing Homes
09/2020	VAM INVESTMENTS	DEMENEGO	ITALY	Ophthalmology
07/2020	ORPEA	BRINDLEY HEALTHCARE	IRELAND	Nursing Homes
06/2020	ASKLEPIOS KLINIKEN	RHÖN-KLINIKUM	GERMANY	Clinics / Hospitals
03/2020	ORPEA	TLC GROUP	IRELAND	Nursing Homes
02/2020	VIVALTO VIE	SOLIMAR	SPAIN	Nursing Homes
02/2020	CLARIANE	INICEA	FRANCE	Clinics / Hospitals
02/2020	AMUNDI PRIVATE EQUITY / SOCIETE GENERALE CAPITAL PARTENAIRES	VIVALTO VIE	FRANCE	Nursing Homes
01/2020	VIVALTO SANTÉ	MATHILDE MÉDICAL DÉVELOPPEMENT	FRANCE	Clinics / Hospitals
01/2020	ARDIAN	SANTE CIE	FRANCE	Health Providers

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LABORIZON by BIOGROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: biogroup